Search results for "glycemia"

showing 10 items of 159 documents

The neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice

2019

International audience; Recent studies have shown that the hypothalamic neuropeptide 26RFa regulates glucose homeostasis by acting as an incretin, and increasing insulin sensitivity. In this study, we further characterized the role of the 26RFa/GPR103 peptidergic system in the global regulation of glucose homeostasis using a 26RFa receptor antagonist, and also assessed whether a dysfunction of the 26RFa/GPR103 system occurs in obese hyperglycemic mice. Firstly, we demonstrate that administration of the GPR103 antagonist reduces the global glucose-induced incretin effect and insulin sensitivity whereas, conversely, administration of exogenous 26RFa attenuates glucose-induced hyperglycemia. U…

Blood GlucoseMaleobesityPhysiologyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]RegulatorMice Obese26RFaMice0302 clinical medicineGlucose homeostasisHomeostasisInsulinglucoseComputingMilieux_MISCELLANEOUSCells Cultured0303 health sciencesdiabetesChemistryincretin[SDV] Life Sciences [q-bio]obésitéAlimentation et NutritionCarbohydrate Metabolismdiabètemedicine.medical_specialtyNeuropeptideIncretin030209 endocrinology & metabolism03 medical and health sciencesPhysiology (medical)Diabetes mellitusInternal medicinemedicineAnimalsHumansglucose homeostasisFood and Nutrition030304 developmental biologyhoméostasieNeuropeptidesIncreasing insulinQRFPNeurosciencesGlucose Tolerance Testmedicine.diseaseMice Inbred C57BLEndocrinologyHyperglycemiaNeurons and Cognitionincretin;glucose homeostasis;26RFa;diabetes;obesity
researchProduct

Properties of erythrocyte light refraction in diabetic patients.

2001

Since hyperglycaemia changes the erythrocyte cell membrane fluidity and impairs cell deformity, our goal was to characterize hemoglobin and red blood cell (RBC) light refractive property changes in diabetic patients. Microscopic investigation was carried out on intact and fixed RBCs. To determine the refractive index (RI): smears of peripheral blood were air dried and fixed for 3 min in methanol. Mixtures of polyvinylpyrolidine and buffer of different pH (1:1) were used as embedding media. Intact RBCs were mixed with a buffered embedding medium, placed on a slide and overlaid with a coverslip. Interference microscopy was used for RI measurements at 18 different pH (pH=2-13). The results sho…

Blood GlucoseOptics and PhotonicsErythrocytesLightBiomedical EngineeringIn Vitro TechniquesBiomaterialsOpticsmedicineDiabetes MellitusHumansScattering RadiationMicroscopy InterferenceChromatographyChemistrybusiness.industryHydrogen-Ion ConcentrationRefractionAtomic and Molecular Physics and OpticsPeripheral bloodElectronic Optical and Magnetic MaterialsRed blood cellmedicine.anatomical_structureCase-Control StudiesHyperglycemiaHemoglobinMicroscopy PolarizationbusinessJournal of biomedical optics
researchProduct

Natural products for the treatment of Type 2 Diabetes Mellitus

2015

Type 2 diabetes mellitus is a metabolic disease characterized by persistent hyperglycemia. High blood sugar can produce long-term complications such as cardiovascular and renal disorders, retinopathy, and poor blood flow. Its development can be prevented or delayed in people with impaired glucose tolerance by implementing lifestyle changes or the use of therapeutic agents. Some of these drugs have been obtained from plants or have a microbial origin, such as galegine isolated from Galega officinalis, which has a great similarity to the antidiabetic drug metformin. Picnogenol, acarbose, miglitol, and voglibose are other antidiabetic products of natural origin. This review compiles the princi…

Blood GlucosePeroxisome Proliferator-Activated ReceptorsPharmaceutical ScienceMedical PlantsPharmacologyAnalytical ChemistryDrug DiscoveryGlucose homeostasisAcarboseClinical Trials as Topicdiabetesbiologyfood and beverages//purl.org/becyt/ford/3.1 [https]Medicina BásicaMolecular Medicine//purl.org/becyt/ford/3 [https]medicine.drugFarmacología y Farmaciamedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDBlood sugarfoodInternal medicineYerba-mateVoglibosemedicineDiabetes MellitusHumansHypoglycemic AgentsGlycoside Hydrolase InhibitorsClinical TrialsPharmacologyBiological Productsclinical trialsPlants Medicinalantidiabeticbusiness.industryMiglitolOrganic ChemistryType 2 Diabetes Mellitusalpha-Glucosidasesbiology.organism_classificationfood.foodEndocrinologyDiabetes Mellitus Type 2Complementary and alternative medicineAntidiabeticHyperglycemiaCiencias MédicasGalega officinalisalpha-Amylasesbusinessmedicinal plants
researchProduct

Advances in pharmacological treatment of type 1 diabetes during pregnancy.

2019

Introduction: In women with type 1 diabetes mellitus (T1DM), pregnancy is associated with a potential risk of maternal, foetal and neonatal outcomes. Stringent metabolic control is required to improve these outcomes. Areas covered: In this review, the authors summarise the current evidence from studies on the pharmacological therapy and on monitoring of T1DM during pregnancy. The authors also discuss the use of new technologies to improve therapeutic management and patient compliance. Expert opinion: Pre-conception counselling is essential in T1DM to minimise pregnancy risks. Pregnancy in T1DM is always considered a high-risk pregnancy. During pregnancy, the target haemoglobin A1C (HbA1c) i…

Blood Glucoseendocrine system diseasesPregnancy in DiabeticsDiabetic complicationBioinformaticsPharmacological treatmenttype 1 diabetes mellitu03 medical and health sciences0302 clinical medicinePregnancymedicineHumansHypoglycemic AgentsInsulinPharmacology (medical)PharmacologyType 1 diabetesPregnancyPotential riskbusiness.industryCesarean Sectionnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseHypoglycemiaglycaemic controlDiabetes Mellitus Type 1Neonatal outcomes030220 oncology & carcinogenesisMetabolic control analysisFemalebusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Clinical Approach to Flash Glucose Monitoring: An Expert Recommendation

2019

The flash glucose monitoring (FGM) system FreeStyle Libre® is a device that measures interstitial glucose in a very simple way and indicates direction and speed of glucose change. This allows persons with diabetes to prevent hypoglycemic and hyperglycemic events. Scientific evidence indicates that the system can improve glycemic control and quality of life. To obtain the maximum benefit, it is necessary to properly handle glucose values and trends. Due to the generalization of the system use, the purpose of the document is to provide recommendations for the optimal use of the device, not only in the management of glucose values and trends but also in the prevention of hypoglycemia, actuati…

Blood Glucosemedicine.medical_specialtyComputer scienceEndocrinology Diabetes and MetabolismBiomedical EngineeringBioengineeringType 2 diabetesHypoglycemiaFlash (photography)Quality of life (healthcare)CommentariesDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinIntensive care medicineRetrospective StudiesGlycemicType 1 diabetesBlood Glucose Self-Monitoringmedicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Quality of LifeInterstitial glucoseJournal of Diabetes Science and Technology
researchProduct

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain.

2020

ObjectiveObservations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings.Research design and methodsDeidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and ≤54 mg/dL), within range (70–180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were desc…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypoglycemialaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusmedicineHumans030212 general & internal medicine1506GlycemicBlood glucose monitoringmedicine.diagnostic_testbusiness.industryBlood Glucose Self-MonitoringEmerging Technologies Pharmacology and Therapeuticsmedicine.diseaseDiabetes Mellitus Type 1GlucosehypoglycemiaSpainCardiologyglycemic controlblood glucose monitoringbusinessReal world dataBMJ open diabetes researchcare
researchProduct

ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism

2014

During the past years, targeted therapies for cancer have been developed using drugs that have significant metabolic consequences. Among them, the mammalian target of rapamycin (mTOR) inhibitors and, to a much lesser extent, the tyrosine kinase inhibitors (TKIs) are involved. mTOR plays a key role in the regulation of cell growth as well as lipid and glucose metabolism. Treatment with mTOR inhibitors is associated with a significant increase in plasma triglycerides and LDL cholesterol. mTOR inhibitors seem to increase plasma triglycerides by reducing the activity of the lipoprotein lipase which is in charge of the catabolism of triglyceride-rich lipoproteins. The increase in LDL cholesterol…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic AgentsHypoglycemiaCarbohydrate metabolismBiologyEndocrinologyInsulin resistanceInternal medicineHyperlipidemiamedicineHomeostasisHumansGlucose homeostasisEnzyme InhibitorsTriglyceridesPI3K/AKT/mTOR pathwayLipoprotein lipaseTOR Serine-Threonine KinasesGeneral MedicineProtein-Tyrosine KinasesLipid Metabolismmedicine.diseaseEndocrinologyLDL receptorCarbohydrate MetabolismEuropean Journal of Endocrinology
researchProduct

Time-in-range for monitoring glucose control: Is it time for a change?

2021

The HbA1c value has been the gold standard for evaluating glucose control for decades. However, it has limitations such as the lack of information on glycemic variability or the risk of hypoglycemia. The increasing use of continuous glucose monitoring has provided patients and healthcare professionals with a range of useful metrics for the management of diabetes. Among them, Time in Range (TIR) is a simple and intuitive metric that gives information regarding the quality of glucose control. It is defined as the time spent in an individual's target glucose range. TIR is strongly correlated with HbA1c, and it has been linked to the risk of developing microvascular and macrovascular complicati…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and MetabolismControl (management)030209 endocrinology & metabolismType 2 diabetesHypoglycemia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicinemedicineRange (statistics)Humans030212 general & internal medicineGlycemicbusiness.industryBlood Glucose Self-MonitoringGeneral MedicineGold standard (test)medicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Diabetes Mellitus Type 2Emergency medicineMetric (unit)businessDiabetes research and clinical practice
researchProduct

Altered cellular magnesium responsiveness to hyperglycemia in hypertensive subjects.

2001

Abstract — — Previous studies by our group have identified ionic aspects of insulin resistance in hypertension, in which cellular responses to insulin were influenced by the basal intracellular ionic environment—the lower the cytosolic free magnesium (Mg i ), the less Mg i increased following insulin stimulation. To investigate whether this ionic insulin resistance represents a more general abnormality of cellular responsiveness in hypertension, we studied Mg i responses to nonhormonal signals such as hyperglycemia (15 mmol/L) and used 31 P-nuclear magnetic resonance (NMR) spectroscopy to measure Mg i in erythrocytes from normal (NL, n=14) and hypertensive (HTN, n=12) subjects before and 3…

Blood Glucosemedicine.medical_specialtyErythrocytesMagnetic Resonance SpectroscopyTime FactorsChemistryInsulinmedicine.medical_treatmentStimulationMetabolismmedicine.diseaseBasal (phylogenetics)Insulin resistanceEndocrinologyGlucoseDiabetes mellitusInternal medicineHyperglycemiaHypertensionInternal MedicinemedicineExtracellularHumansMagnesiumHormoneHypertension (Dallas, Tex. : 1979)
researchProduct

Psychosocial Aspects of Continuous Glucose Monitoring

2016

Continuous glucose monitoring (CGM) systems provide people with diabetes with valuable real-time information on glucose trajectories and trends, thus offering opportunities for improving diabetes self-management. Ample evidence from clinical trials underscores CGM effectiveness for biomedical outcomes including HbA1C and hypoglycemia. However, interindividual variability in CGM uptake seems to be substantial: Neither do all individuals with diabetes adopt CGM readily in their diabetes self-management, nor do all of them benefit from CGM. In this article, we focus on CGM effects on quality of life and the potential role of psychosocial patient characteristics for determining the uptake and …

Blood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringPatient characteristics030209 endocrinology & metabolismBioengineeringHypoglycemia03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Diabetes mellitusDiabetes MellitusInternal MedicinemedicineHumans030212 general & internal medicineSpecial Section: Psychological Factors for Diabetes Technology Part IIIntensive care medicineContinuous glucose monitoringbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesmedicine.diseaseClinical diabetesClinical trialQuality of LifebusinessPsychosocialJournal of Diabetes Science and Technology
researchProduct